International society of geriatric oncology chemotherapy taskforce: Evaluation of chemotherapy in older patients - An analysis of the medical literature Journal Article
| Authors: | Lichtman, S. M.; Wildiers, H.; Chatelut, E.; Steer, C.; Budman, D.; Morrison, V. A.; Tranchand, B.; Shapira, I.; Aapro, M. |
| Article Title: | International society of geriatric oncology chemotherapy taskforce: Evaluation of chemotherapy in older patients - An analysis of the medical literature |
| Abstract: | The elderly comprise the majority of patients with cancer and are the recipients of the greatest amount of chemotherapy. Unfortunately, there is a lack of data to make evidence-based decisions with regard to chemotherapy. This is due to the minimal participation of older patients in clinical trials and that trials have not systematically evaluated chemotherapy. This article reviews the available information with regard to chemotherapy and aging provided by a task force of the International Society of Geriatric Oncology (SIOG). Due to the lack of prospective data, the conclusions and recommendations made are a consensus of the participants. Extrapolation of data from younger to older patients is necessary, particularly to those patients older than 80 years, for which data is almost entirely lacking. The classes of drugs reviewed include alkylators, antimetabolites, anthracyclines, taxanes, camptothecins, and epipodophyllotoxins. Clinical trials need to incorporate an analysis of chemotherapy in terms of the pharmacokinetic and pharmacodynamic effects of aging. In addition, data already accumulated need to be reanalyzed by age to aid in the management of the older cancer patient. © 2007 by American Society of Clinical Oncology. |
| Keywords: | cancer chemotherapy; treatment response; aged; aged, 80 and over; fludarabine; prednisone; clinical trial; drug tolerability; fatigue; neutropenia; review; cisplatin; doxorubicin; fluorouracil; area under the curve; diarrhea; drug dose reduction; drug potentiation; recommended drug dose; side effect; unspecified side effect; antineoplastic agents; capecitabine; paclitaxel; adjuvant therapy; cytarabine; methotrexate; temozolomide; neurotoxicity; antineoplastic agent; neoplasm; neoplasms; medical decision making; carboplatin; unindexed drug; consensus; multiple cycle treatment; multiple myeloma; nephrotoxicity; sensory neuropathy; breast cancer; bone marrow suppression; etoposide; blood toxicity; leukopenia; lung non small cell cancer; mucosa inflammation; nausea; stomatitis; thrombocytopenia; vomiting; peripheral neuropathy; camptothecin; risk factors; combination chemotherapy; alkylating agent; cyclophosphamide; melphalan; vincristine; kidney failure; age factors; risk factor; ifosfamide; hodgkin disease; age; docetaxel; colorectal carcinoma; hypomagnesemia; drug fatality; drug distribution; drug mechanism; kidney function; systematic review; folinic acid; cardiotoxicity; mitoxantrone; medical society; epirubicin; medical literature; aging; drug metabolism; drug absorption; drug blood level; ketoconazole; drug half life; anthracycline derivative; navelbine; oxaliplatin; hand foot syndrome; fluoropyrimidine derivative; meta analysis; drug binding; drug excretion; clinical trials; creatinine clearance; geriatrics; cardiomyopathy; drug formulation; levamisole; intrahepatic cholestasis; nifedipine; auditory system |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 25 |
| Issue: | 14 |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2007-05-10 |
| Start Page: | 1832 |
| End Page: | 1843 |
| Language: | English |
| DOI: | 10.1200/jco.2007.10.6583 |
| PUBMED: | 17488981 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 85" - "Export Date: 17 November 2011" - "CODEN: JCOND" - "Source: Scopus" |
